Mechelle Perry
Nurse Practitioner · Medina, TNNPI 1225150667
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 507 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 37 manufacturers reported payments, led by AbbVie at 24.1% of the total. Among nurse practitioner clinicians in TN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 507 payments — averaging $23.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$3K
- Novo Nordisk$2K
- Lilly USA, LLC$899
- Bayer$566
- AstraZeneca$505
- Biohaven Pharmaceuticals, Inc.$503
- plus $5K from 31 others
What the payments were for
- Food & beverage$11,831100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 128 | $2,847 |
| Novo Nordisk | 65 | $1,814 |
| Lilly USA, LLC | 58 | $899 |
| Bayer | 25 | $566 |
| AstraZeneca | 13 | $505 |
| Biohaven Pharmaceuticals, Inc. | 17 | $503 |
| Pfizer | 31 | $406 |
| Johnson & Johnson | 13 | $365 |
| GSK | 13 | $324 |
| Axsome Therapeutics, Inc. | 6 | $324 |
| Vanda Pharmaceuticals Inc. | 15 | $312 |
| Otsuka America Pharmaceutical, Inc. | 11 | $301 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 10 | $270 |
| Lundbeck LLC | 7 | $241 |
| Amarin Pharma, Inc. | 13 | $210 |
| Biohaven Pharmaceutical Holding Company Ltd. | 8 | $180 |
| Idorsia Pharmaceuticals US Inc | 10 | $179 |
| Phathom Pharmaceuticals, Inc. | 5 | $170 |
| Astellas Pharma US Inc | 4 | $168 |
| Boehringer Ingelheim | 8 | $138 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 8 | $131 |
| Ardelyx, Inc. | 1 | $125 |
| Neurocrine Biosciences, Inc. | 1 | $120 |
| Merck | 1 | $107 |
| Novartis | 7 | $100 |
| Dexcom, Inc. | 2 | $97 |
| Amgen | 7 | $97 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $63 |
| Sanofi-aventis U.S. LLC | 3 | $53 |
| Teva Pharmaceuticals USA, Inc. | 4 | $52 |
| Azurity Pharmaceuticals, Inc. | 2 | $34 |
| Eisai Inc. | 2 | $29 |
| Pulmonx Corporation | 1 | $26 |
| Abbott | 1 | $24 |
| Exact Sciences | 1 | $20 |
| Mylan Specialty L.p. | 1 | $16 |
| Bardy Diagnostics, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$11,831 in reported general payments places this provider in the 95th percentile of 2,662 nurse practitioner providers in Tennessee.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 164 | $162,785 |
| MounjaroTirzepatide | 28 | $33,193 |
| EliquisApixaban | 24 | $24,614 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 26 | $16,822 |
| RybelsusSemaglutide | 11 | $12,677 |
| XareltoRivaroxaban | 23 | $12,560 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 371 | $10,910 |
| Emgality PenGalcanezumab-Gnlm | 13 | $9,238 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 12 | $7,214 |
| JanuviaSitagliptin Phosphate | 12 | $6,434 |
| Tresiba Flextouch U-100Insulin Degludec | 12 | $4,248 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 138 | $3,666 |
| Dalfampridine ErDalfampridine | 12 | $3,460 |
| SymbicortBudesonide/Formoterol Fumarate | 12 | $2,834 |
| Dexlansoprazole DrDexlansoprazole | 12 | $2,568 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $1,814 | $175,461175 claims |
| Lilly USA, LLCMounjaro, Humalog | $899 | $34,93741 claims |
| PfizerEliquis | $406 | $24,61424 claims |
| GSKTrelegy Ellipta | $324 | $16,82226 claims |
| Johnson & JohnsonXarelto | $365 | $12,56023 claims |
| Boehringer IngelheimSynjardy Xr | $138 | $7,21412 claims |
| MerckJanuvia | $107 | $6,43412 claims |
| AstraZenecaSymbicort | $505 | $2,83412 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,662 nurse practitioner providers in Tennessee.
Other nurse practitioner in Medina
- Darren PerryMedina$14K
- Amy HatcherMurfreesboro$1.1M
- Karen RodenKnoxville$265K
- Susan UtleyNashville$194K
- Whitney EricksonMemphis$159K
- Erica HembreeKnoxville$125K
- Brooke FaughtNashville$87K
- Lauren WelchNashville$71K
- Cara StoutKingsport$71K
- S Marie HamiltonOoltewah$64K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.